BUFLOMEDIL

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H25NO4
Molecular Weight	307.3847
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC(OC)=C(C(=O)CCCN2CCCC2)C(OC)=C1

InChI

InChIKey=OWYLAEYXIQKAOL-UHFFFAOYSA-N

InChI=1S/C17H25NO4/c1-20-13-11-15(21-2)17(16(12-13)22-3)14(19)7-6-10-18-8-4-5-9-18/h11-12H,4-10H2,1-3H3

HIDE SMILES / InChI

Molecular Formula	C17H25NO4
Molecular Weight	307.3847
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3297620
Curator's Comment: description was created based on several sources, including https://www.drugs.com/international/buflomedil.html | https://www.ncbi.nlm.nih.gov/pubmed/3784966 | https://www.ncbi.nlm.nih.gov/pubmed/26193704 | http://www.medscape.com/viewarticle/753768

Buflomedil (trade name Loftyl) is a vasoactive drug used to treat claudication or the symptoms of peripheral arterial disease. Buﬂomedil has been used for people with diseases of the leg arteries and has shown some beneﬁts for people with a previous stroke. The most common type of stroke is due to narrowing or blockage of an artery in the brain (i.e. ischaemic stroke). Buﬂomedil is a drug that can dilate brain blood vessels, which may have beneﬁt for people with ischaemic stroke. However, it has not been approved to treat stroke in clinical practice. In 2012 the European Medicines Agency has completed a review of the safety and effectiveness of buflomedil-containing medicines, both oral and injectable, due to severe neurological and cardiac side effects seen with buflomedil. The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of buflomedil do not outweigh its risks, and has recommended that all marketing authorisations for medicines containing buflomedil should be suspended throughout the European Union (EU).

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
3-beta-hydroxysteroid-delta(8),delta(7)-isomerase 7 Target ID: CHEMBL4931 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16033255	Inhibitor 8504		60.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Peripheral arterial disease 22 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3721052	Primary		Approved 8583	Buflomedil Approved Use Unknown
Ischemic stroke 35 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26193704	Primary		Not Provided 511	Buflomedil Approved Use Unknown

AUC

Value	Dose	Analyte	Population
2.32 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7286057/	50 mg single, intravenous dose: 50 mg route of administration: Intravenous experiment type: SINGLE co-administered:	BUFLOMEDIL serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.52 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7286057/	100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered:	BUFLOMEDIL serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9.26 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7286057/	200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	BUFLOMEDIL serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
3.29 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7286057/	50 mg single, intravenous dose: 50 mg route of administration: Intravenous experiment type: SINGLE co-administered:	BUFLOMEDIL serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.07 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7286057/	100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered:	BUFLOMEDIL serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.39 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7286057/	200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	BUFLOMEDIL serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
300 mg 2 times / day multiple, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1673051/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/1673051/	Sources: https://pubmed.ncbi.nlm.nih.gov/1673051/

PubMed

Title	Date	PubMed
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.	2011-07-14	21599003
Influence of pharmacological treatment on blood flow and muscle perfusion in patients with obliterative atheromatosis assessed with isotopic methods. A pilot study.	2010-12	21119581
[Addition of antithrombosis in situ in the case of digital replantation: preliminary prospective study of 13 cases].	2010-10	20452806
Silence of the limbs pharmacological symptomatic treatment of intermittent claudication.	2010-05	19485897
[Multicentric study of thrombosis prevention in upper-extremity microsurgery. Survey at the Fesum centers].	2010-04	20299262
Surgical management of a diabetic calcaneal ulceration and osteomyelitis with a partial calcanectomy and a sural neurofasciocutaneous flap.	2010	22396813
Buflomedil: potential new indications for an old agent.	2009-06	19174750
Pharmacologic therapy for intermittent claudication.	2009-05	19397462
Endothelin and sex hormones modulate the fibronectin synthesis by cultured human skin scleroderma fibroblasts.	2009-04	18952637
[Severe peripheral ischemia of rare origin].	2009-03-19	19292095
Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data.	2009-03-10	19276131
Cutaneous granulomatous reaction from mesotherapy.	2009-02	19215273
Effects of buflomedil and pentoxifylline on hamster skin-flap microcirculation: prediction of flap viability using orthogonal polarization spectral imaging.	2009	19690666
Bias in benefit-risk appraisal in older products: the case of buflomedil for intermittent claudication.	2009	19388720
Letter by De Backer et al regarding article, "Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study".	2008-09-02	18765384
Oral vasodilators for primary Raynaud's phenomenon.	2008-04-16	18425964
Effectiveness of mesotherapy on body contouring.	2008-04	18349597
Simultaneous FTIR spectroscopic imaging and visible photography to monitor tablet dissolution and drug release.	2008-04	17612794
The use of buflomedil in reduction mammaplasty for a previously irradiated breast: a case report.	2008-03	18058164
Buflomedil in peripheral arterial disease: trials and tribulations.	2008-02-12	18268159
Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study.	2008-02-12	18212283
Buflomedil for intermittent claudication.	2008-01-23	18253982
Long-term follow-up of hypothenar hammer syndrome: a series of 47 patients.	2007-11	18004178
Buflomedil for intermittent claudication.	2007-10-17	17943749
Sensitive and rapid LC-ESI-MS method for the determination of trimetazidine in human plasma.	2007-06-28	17349764
[Adenosine for treatment of ischemic pain in thromboangiitis obliterans. A case report].	2007-06	17265013
Buflomedil: still seizures and cardiac disorders. Too many patients are exposed to an unjustified risk of serious adverse effects.	2007-02	17323522
Preclinical and clinical examinations of Salvia miltiorrhiza and its tanshinones in ischemic conditions.	2006-11-23	17302964
The effects of prostaglandin E-1 in patients with intermittent claudication.	2006-06	16787192
Comparison between intravenous iloprost and vasoactive drugs in limb ischemia IIB severe. A retrospective analysis.	2006-06	16733512
Assemblage of novel release modules for the development of adaptable drug delivery systems.	2006-03-10	16458384
Detailed documentation of one lipolysis treatment: blood values, histology, and ultrasound findings.	2006-02-19	19341647
Facilitated column selection in pharmaceutical analyses using a simple column classification system.	2006-01-06	16242136
Buflomedil and pentoxifylline in the viability of dorsal cutaneous flaps of rats treated with nicotine.	2006	16756255
[Pharmaceutical analysis and validation of hospital prescriptions, a 5-year study].	2005-08-27	16225250
Does Danshen improve disability after acute ischaemic stroke?	2005-02	15644072
Effect of loading on a swelling-controlled drug delivery system studied by optical techniques.	2005-01-03	15719503
Therapy of hearing disorders - conservative procedures.	2005	22073049
Local hyperemia to heating is impaired in secondary Raynaud's phenomenon.	2005	16207327
Protective effect of buflomedil in a rat model of moderate cerebral ischemia.	2005	16149710
Inhibitory effect of buflomedil on prostate alpha1A adrenoceptor in the Wistar rat.	2004-09-02	15331158
Rapid and sensitive liquid chromatography-electrospray ionization-mass spectrometry method for the determination of eperisone in human plasma: method and clinical applications.	2004-06-11	15189598
[Secondary prevention and conservative therapy of obliterative arteriosclerosis].	2004-05-16	15202325
[Suicidal buflomedil intoxication].	2004-05-13	15137632
Development of pulsatile release tablets with swelling and rupturable layers.	2004-03-05	14980764
Suicide by buflomedil HCl: a case report.	2004-02	15261008
Drug treatment of intermittent claudication.	2004	15257627
[Sudden hearing loss. Clinical case].	2002	12596353
Ticlopidine-pentoxifylline combination in the treatment of atherosclerosis and the prevention of cerebrovascular accidents.	1989-01-01	2651175
[Emetic and catalepsy-inducing actions of buflomedil].	1988-12	3250915

Patents

Sample Use Guides

In Vivo Use Guide

600 mg/day

Route of Administration: Oral

In Vitro Use Guide

The effect of buflomedil (Fonzylane; Laboratoire Lafon, Maisons-Alfort, France) on platelet function, a drug used clinically for the treatment of peripheral vascular diseases, was investigated in vitro. The compound significantly inhibits epinephrine-induced aggregation at the micromolar level. At higher doses (approximately 1 mM), a weak inhibition of ADP- and collagen-induced aggregation was observed; at these concentrations, buflomedil inhibits granular secretion and the interaction of fibrinogen with its receptor on platelet. Further investigations indicate that the drug affects calcium uptake at the membrane level and inhibits the binding of [3H]-yohimbine to the same extent as observed with phentolamine. The IC50 determined from competition binding assays was 1 +/- 0.5 microM.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:19:23 GMT 2025` Edited by `admin` on `Mon Mar 31 18:19:23 GMT 2025`
Record UNII	V7I71DQ432
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BUFLOMEDIL

Official Name

English

BUFLOMEDIL [MI]

Preferred Name

English

Buflomedil [WHO-DD]

Common Name

English

buflomedil [INN]

Common Name

English

2',4',6'-TRIMETHOXY-4-(1-PYRROLIDINYL)BUTYROPHENONE

Systematic Name

English

Classification Tree Code System Code

WHO-ATC

C04AX20